The most common genetic variants in NSCLC mainly include epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene fusion, tyrosine kinase hepatocyte growth factor receptor (HGFR, also known as MET) amplification, Kirsten rat sarcoma (KRAS) mutations, ROS1 proto-oncogene rearrangement, rearranged during transfection (RET) gene fusion, and inactivation of tumor suppressor P53 and liver kinase B1 (LKB1) [4–8]. The gene discussed is MET; the disease is non-small cell lung carcinoma.